Abstracts tagged "DMARDs"

Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting
Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis
Ichiro Miki¹ and Masako Uchii², ¹Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, ²Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan
Background/Purpose: Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Sarah Ringold¹, Pamela F. Weiss², Robert A. Colbert³, Esi Morgan DeWitt⁴, Tzielan C. Lee⁵, Karen Onel⁶, Sampath Prahalad⁷, Rayfel Schneider⁸, Susan Shenoi⁹, Richard K. Vehe¹⁰ and Yukiko Kimura¹¹, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³NIAMS NIH, Bethesda, MD, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁷Pediatrics, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁹Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, ¹⁰Department of Pediatrics, University of Minnesota, Minneapolis, MN, ¹¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…
Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Ozgur Tunceli¹, Jeffrey R. Curtis², Tatia C. Woodward³, Siting Zhou¹, Yen-Wen Chen⁴ and Ancilla W. Fernandes³, ¹HealthCore, Inc., Wilmington, DE, ²Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ³MedImmune, LLC, Gaithersburg, MD, ⁴HealthCore, Inc, Wilmington, DE
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 928 • 2012 ACR/ARHP Annual Meeting
Is There an Optimal Treatment Strategy for Disease-Modifying-Antirheumatic-Drug Naïve Patients with Rheumatoid Arthritis?
Roopa Akkineni¹ and Daniel A. Albert², ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: There is a lack of head-to-head clinical trial data to determine the most effective treatment for rheumatoid arthritis (RA). However, these trials have had…
Abstract Number: 2546 • 2012 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial
Désirée van der Heijde¹, Robert B. M. Landewé² and David Gruben³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ³Pfizer Inc., Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the ORAL Scan trial…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy
Edward Bernton¹, Eduard Krantz² and William Gannon Jr.³, ¹Protalex Inc., Summit, NJ, ²Parexel Clinical Pharmacology, Bloemfontein, South Africa, ³Capital City Technical Consulting, Inc., Washington, DC
Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …
Abstract Number: 2545 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients with Moderate to Severe RA
G. R. Burmester¹, Andrea Rubbert-Roth², Alain G. Cantagrel³, Stephen Hall⁴, Piotr Leszczynski⁵, Daniel Feldman⁶, Madura J. Rangaraj⁷, Georgia Roane⁸, Charles L. Ludivico⁹, Francesco Ramirez¹⁰ and Min Bao¹¹, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum der Universität zu Köln, Köln, Germany, ³Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁴Cabrini Medical Centre, Malvern, Australia, ⁵Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁶Rheumatology, Universidade Federal de de São Paulo, Sao Paulo, Brazil, ⁷Arthritis & Diabetes Clinic, Inc., Monroe, LA, ⁸Rheumatology Associates of South Carolina, Charleston, SC, ⁹East Penn Rheumatology Assoc, Bethlehem, PA, ¹⁰Roche Products Limited, Welwyn, United Kingdom, ¹¹Genentech, South San Francisco, CA
Background/Purpose: The objective of this study was to compare the efficacy and safety of tocilizumab (TCZ) subcutaneous (SC) and TCZ intravenous (IV) regimen in patients…
Abstract Number: 1560 • 2012 ACR/ARHP Annual Meeting
What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review
Annelieke Pasma¹, Adriaan van 't Spijker², Jan van Busschbach³, Johanna M.W. Hazes⁴ and Jolanda J. Luime⁵, ¹Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Medical Psychology and Psychotherapy, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: In the early stages of Rheumatoid Arthritis (RA), adherence to the prescribed treatment is important to prevent irreversible joint damage. However, medication adherence rates…
Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S. Smolen¹, D. Aletaha², D. Gruben³, J. D. Bradley⁴, S. H. Zwillich³, S. Krishnaswami³, B. Benda⁵ and C. Mebus⁶, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Pfizer Inc., Groton, CT, ⁴Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, ⁵Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
Abstract Number: 2486 • 2012 ACR/ARHP Annual Meeting
Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Eun Bong Lee¹, Roy Fleischmann², Stephen Hall³, Ronald F. van Vollenhoven⁴, John Bradley⁵, David Gruben⁶, Tamas Koncz⁷, Sriram Krishnaswami⁵, Gene Wallenstein⁶, Samuel H. Zwillich⁵, Bethanie E. Wilkinson⁶ and the ORAL Start Investigators⁸, ¹Seoul National University, Seoul, South Korea, ²Metroplex Clinical Research Center, Dallas, TX, ³Cabrini Medical Centre, Melbourne, Australia, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc., Groton, CT, ⁷Pfizer Inc., New York, NY, ⁸Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This Phase 3, 24-mo study (ORAL…
Abstract Number: 1573 • 2012 ACR/ARHP Annual Meeting
Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti-Rheumatic Drugs: Does an Educational Intervention Change Practice in an Outpatient Clinic?
Debra C. Lloyd¹, John N. Mecchella² and Daniel Albert³, ¹Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ²Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH
Background/Purpose: In 2008, the American College of Rheumatology (ACR) developed recommendations for use of non-biologic and biologic DMARDs in the treatment of rheumatoid arthritis (RA). …
Abstract Number: 566 • 2012 ACR/ARHP Annual Meeting
Effect of TNF Antagonists On Radiographic Progression in Psoriatic Arthritis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Radjiv Goulabchand¹, Gael Mouterde¹, Cédric Lukas², Thomas Barnetche³, Jacques Morel¹ and Bernard Combe¹, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France
Background/Purpose: Psoriatic arthritis (PsA) can cause important structural damages which can lead to disability. TNF antagonists have shown their clinical efficacy in PsA, but only…
Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis
K. L. Winthrop¹, H. Valdez², E. Mortensen³, R. Chew⁴, S. Krishnaswami⁵, T. Kawabata⁵ and R. Riese⁴, ¹Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ²Pfizer Inc., New York, NY, ³Global Medical Affairs, Pfizer Inc., Collegeville, PA, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.